Tag: Merck

The Merck Group, branded and commonly known as Merck, is a German multinational chemical, pharmaceutical and life sciences company headquartered in Darmstadt, with around 50,000 employees in around 70 countries. Merck was founded in 1668 and is the world’s oldest operating chemical and pharmaceutical company, as well as one of the largest pharmaceutical companies in the world.

Merck Acquires Immune Design for $300m

Merck, known as MSD outside the United States and Canada, and Immune Design, today announced that the companies have entered into a definitive agreement under which Merck, through a subsidiary, will a...

Keytruda Received Another FDA Approval

Merck, known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved KEYTRUDA, Merck’s anti-PD-1 therapy, for the adjuvant treatment ...

Saudi Universities Signed MoU with Merck

Three Saudi universities — King Saud University, Princess Noura Bint Abdul Rahman University, and Qassim University — have taken a qualitative step toward achieving Vision 2030 goals by signing a Memo...

Priority Review for Merck and Pfizer’s Treatment

EMD Serono, the biopharmaceutical business of Merck KGaA, Darmstadt, Germany in the US and Canada, and Pfizer Inc. has announced that the US Food and Drug Administration (FDA) had accepted for Priorit...

Merck Expands US R&D Facility

Merck KGaA, which operates its biopharmaceutical business as EMD Serono in the U.S. and Canada, is investing $70 million to expand its R&D facility in Billerica, MA. The new 145,000 sq.-ft. buildi...

Merck Expands R&D Facility

German drugs and Chemical group Merck KGaA announced a $70 million investment to expand its state of the art research and development (R&D) facility in Billerica, Massachusetts. The new buildin...

Big Pharma to Testify in High Drug Pricing Case

While congressional scrutiny on drug pricing is nothing new, the prospect of some of the pharmaceutical industry's highest-profile CEOs testifying on the issue will make for a must-watch event. In ...

GSK and Merck to Develop Cancer Treatment under €3.7bn Deal

GlaxoSmithKline (GSK) and Merck will develop and commercialize novel immunotherapy to treat multiple cancers, under €3.7bn worth deal. The M7824 is an investigational bifunctional fusion protein im...

Merck is Top Pick according to Bank of America

Bank of America Merrill Lynch on Tuesday named Merck its top pick among the many U.S. pharmaceutical stocks thanks to the growing success of its key cancer drug, Keytruda. Merck looks well positioned...

Merck’s Drug Won Breakthrough Therapy Designation

Merck, known as MSD outside of the United States and Canada, today announced that V114, the company’s investigational 15-valent pneumococcal conjugate vaccine, has received Breakthrough Therapy Design...

Keytruda to Reduce Death Risk by 31%

Merck
Merck, known as MSD outside the United States and Canada, announced the first presentation of results from KEYNOTE-181, a Phase 3 trial investigating KEYTRUDA, Merck’s anti-PD-1 therapy, as monotherap...

Merck and Pfizer’s Cancer Drug Failed Second Trial

Merck KGaA and Pfizer PD-L1 inhibitor Bavencio has missed the mark in its second ovarian cancer trial in a month, this time failing in previously-untreated patients. Results from a planned interim ...

Revolutionised Treatments of Advanced Melanoma

Checkpoint inhibitors have already revolutionised the treatment of advanced melanoma, and Merck & Co has just claimed approval for even earlier use of its Keytruda product in Europe. The Europe...

MSD acquires an Australian biotechnology company

merck
Merck and Viralytics Limited announced that the companies have signed a definitive agreement under which Merck will acquire Viralytics, an Australian company focused on oncolytic immunotherapy treatments for a range of cancers.

Merck will buy Rigontec to firm up its leadership in immuno-oncology

merck
Merck, known as MSD, and Rigontec today announced that Merck will acquire Rigontec

Merck KGaA will colaborate with F-star on cancer immunotherapy

merck
Merck, a leading science and technology company, announced a new strategic collaboration with biopharmaceutical company F-star